PCM
CDLX icon

Prelude Capital Management’s Cardlytics CDLX Stock Holding History

Prelude Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,007
Closed -$436K – 1245
2024
Q1 		$436K Buy
3,007
+330
+12% +$27.9K 0.02% 693
2023
Q4 		$247K Buy
+2,677
New +$272K 0.02% 837
2021
Q3 		– Sell
-192
Closed -$243K – 1775
2021
Q2 		$243K Buy
+192
New +$217K 0.01% 1295
2019
Q3 		– Sell
-12,938
Closed -$3.36M – 1732
2019
Q2 		$3.36M Buy
12,938
+1,513
+13% +$303K 0.17% 98
2019
Q1 		$1.89M Buy
11,425
+2,933
+35% +$477K 0.11% 197
2018
Q4 		$920K Buy
+8,492
New +$1.43M 0.06% 335

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's CDLX Position: Q2 2024 in Review

Prelude Capital Management sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 3,007 shares — an estimated $436K sold.

Prelude Capital Management first reported a position in CDLX in Q4 2018 and held it in 6 quarters. The position peaked at $3.36M in Q2 2019. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

  • Prelude Capital Management reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 3,007 Cardlytics shares in Q2 2024, an estimated $436K.
  • Prelude Capital Management first reported a position in Cardlytics in Q4 2018 and held it in 6 quarters.
  • Prelude Capital Management's Cardlytics position peaked at $3.36M in Q2 2019.
  • 127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.